Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. (May 2023)
- Record Type:
- Journal Article
- Title:
- Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. (May 2023)
- Main Title:
- Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis
- Authors:
- Bassir Nia, Anahita
Gibson, Claire L
Spriggs, Sharron A
Jankowski, Samantha E
DeFrancisco, Daniel
Swift, Amy
Perkel, Charles
Galynker, Igor
Honrao, Chandrashekhar
Makriyannis, Alexandros
Hurd, Yasmin L - Abstract:
- Background: Cannabis use suppresses the endocannabinoid system in healthy individuals. However, the association between cannabis use with the endocannabinoid system is understudied in individuals with psychosis despite the high rate of cannabis use in these individuals. Methods: We enrolled 83 individuals who were admitted to an inpatient psychiatric unit with psychotic presentations, and measured their plasma levels of main endocannabinoids, Anandamide (AEA) and 2-Acylglycerol (2-AG), and endocannabinoid related compounds, Palmitoylethanolamine, and N-oleoylethanolamine. Cannabis use was assessed with urine toxicology and frequency of cannabis use was assessed using self-reported questionnaires. The Positive and Negative Syndrome Scale was used to assess the severity of psychotic symptoms. Results: Overall, we had 38 individuals in cannabis positive group (CN+) and 45 individuals in cannabis negative group (CN−). Compared to CN−, CN+ group had lower plasma levels of AEA, which remained significant after controlling for age, gender, race/ethnicity, and use of other drugs. Conclusion: Cannabis use is associated with low plasma AEA levels in individuals with psychosis, which is in the same line with reported suppressive effects of cannabis on the endocannabinoid system in healthy individuals. Further studies are needed to investigate the clinical significance of this finding.
- Is Part Of:
- Journal of psychopharmacology. Volume 37:Number 5(2023)
- Journal:
- Journal of psychopharmacology
- Issue:
- Volume 37:Number 5(2023)
- Issue Display:
- Volume 37, Issue 5 (2023)
- Year:
- 2023
- Volume:
- 37
- Issue:
- 5
- Issue Sort Value:
- 2023-0037-0005-0000
- Page Start:
- 484
- Page End:
- 489
- Publication Date:
- 2023-05
- Subjects:
- Psychosis -- endocannabinoid -- anandamide -- cannabis
Psychopharmacology -- Periodicals
615.78 - Journal URLs:
- http://jop.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/02698811221148604 ↗
- Languages:
- English
- ISSNs:
- 0269-8811
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26456.xml